Skip to main content
Rapid Dose Therapeutics Corp logo

Rapid Dose Therapeutics Corp — Investor Relations & Filings

Ticker · DOSE ISIN · CA75339A1012 CSE Manufacturing
Open in API
Filings indexed 490 across all filing types
Latest filing 2024-07-26 Capital/Financing Update
Country CA Canada
Listing CSE DOSE

About Rapid Dose Therapeutics Corp

https://rapid-dose.com/

Rapid Dose Therapeutics Corp. is a pharma-technology company specializing in proprietary drug delivery technologies engineered to enhance patient outcomes and quality of life. The core business revolves around an innovative oral delivery platform utilizing sublingual thin film strip technology. The company's flagship product, QuickStrip™, is a fast-dissolving system designed for the rapid release of pharmaceuticals, micronized oils, and over-the-counter medicines. QuickStrip™ is distinguished by its ability to achieve blood concentrations comparable to intravenous injection, offering superior bioavailability and rapid onset. RDT provides product innovation, production, and consultation services to the pharmaceutical and healthcare manufacturing sectors for both prescription and non-prescription applications.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details a material change event dated July 19, 2024, specifically the closing of the first tranche of an equity private placement financing. It includes a summary and full description of the financing event, with proceeds and share issuance details. The document is a regulatory filing reporting a material change rather than a full financial report or earnings release. It is not an annual or interim report, nor a call transcript or management discussion. The content aligns with a Capital/Financing Update as it announces a financing event and capital raise. The document length (6732 characters) supports it being a full report rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-07-26 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis May 31, 2024' and contains detailed discussion and analysis of the company's financial condition and results of operations for the three-month period ended May 31, 2024. It includes financial figures, business overview, forward-looking statements, and operational details. The presence of substantive financial data and management commentary indicates this is a Management Discussion and Analysis (MD&A) report. The document is not an earnings release (which would be shorter and more summary), nor is it a full annual or interim report with full financial statements, but it is a comprehensive management report explaining financial results and business trends for a quarterly period. Therefore, the appropriate classification is Management Reports (MDA).
2024-07-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for Rapid Dose Therapeutics Corp. for the three months ended May 31, 2024 and 2023. It contains detailed unaudited financial statements including statements of financial position, loss and comprehensive loss, changes in shareholders' deficit, and cash flows. The presence of actual financial data and analysis for a period shorter than a full fiscal year (quarterly) confirms this is an interim financial report. The document is approximately 15,000 characters long, indicating it is the full report, not just an announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2025
2024-07-26 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2024-07-26 English
Notice of the meeting and record date (amended) - English.pdf
AGM Information Classification · 90% confidence The document is a short notice confirming the record and meeting dates for the upcoming Annual General Meeting (AGM) of Rapid Dose Therapeutics Corp. It includes details such as the record date, meeting date, classes of securities entitled to vote, and mailing dates. There is no detailed presentation or materials from the AGM itself, nor is there any financial data or results disclosed. The document serves as an announcement related to the AGM logistics rather than the AGM materials or report. Given the short length (1899 characters) and the nature of the content, it fits best as an AGM Information announcement or related notice. However, since it is primarily a confirmation of notice and meeting dates rather than the AGM materials themselves, it aligns most closely with the AGM Information category (AGM-R), which covers presentations and materials shared during the AGM or related notices about the AGM.
2024-07-22 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of the first tranche of a private placement equity financing by Rapid Dose Therapeutics Corp. It details the amount raised, the number of shares issued, the price per share, and the intended use of proceeds. There is no financial statement or detailed financial analysis included, only an announcement of a financing event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other filing types. The document length is about 5406 characters, which is consistent with a typical announcement rather than a full report. Therefore, the appropriate classification is CAP.
2024-07-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.